172 related articles for article (PubMed ID: 25582722)
21. Therapeutic drug monitoring of teicoplanin using an LC-MS/MS method: Analysis of 421 measurements in a naturalistic clinical setting.
Jung J; Lee K; Oh J; Choi R; Woo HI; Park HD; Kang CI; Kim YJ; Lee SY
J Pharm Biomed Anal; 2019 Apr; 167():161-165. PubMed ID: 30776754
[TBL] [Abstract][Full Text] [Related]
22. Current role of LC-MS in therapeutic drug monitoring.
Saint-Marcoux F; Sauvage FL; Marquet P
Anal Bioanal Chem; 2007 Aug; 388(7):1327-49. PubMed ID: 17520242
[TBL] [Abstract][Full Text] [Related]
23. A liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for monitoring drug exposure in hematopoietic stem cell transplant recipients.
Laverdière I; Caron P; Couture F; Lévesque E; Guillemette C
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Feb; 885-886():131-7. PubMed ID: 22265668
[TBL] [Abstract][Full Text] [Related]
24. Simultaneous measurement of cyclosporin A and tacrolimus from dried blood spots by ultra high performance liquid chromatography tandem mass spectrometry.
Hinchliffe E; Adaway JE; Keevil BG
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Feb; 883-884():102-7. PubMed ID: 21680259
[TBL] [Abstract][Full Text] [Related]
25. A multiplex liquid chromatography tandem mass spectrometry method for the quantification of seven therapeutic monoclonal antibodies: Application for adalimumab therapeutic drug monitoring in patients with Crohn's disease.
Willeman T; Jourdil JF; Gautier-Veyret E; Bonaz B; Stanke-Labesque F
Anal Chim Acta; 2019 Aug; 1067():63-70. PubMed ID: 31047150
[TBL] [Abstract][Full Text] [Related]
26. Usage and limitations of liquid chromatography-tandem mass spectrometry (LC-MS/MS) in clinical routine laboratories.
Seger C
Wien Med Wochenschr; 2012 Nov; 162(21-22):499-504. PubMed ID: 23129542
[TBL] [Abstract][Full Text] [Related]
27. Two rapid ultra performance liquid chromatography/tandem mass spectrometry (UPLC/MS/MS) methods with common sample pretreatment for therapeutic drug monitoring of immunosuppressants compared to immunoassay.
Tszyrsznic W; Borowiec A; Pawlowska E; Jazwiec R; Zochowska D; Bartlomiejczyk I; Zegarska J; Paczek L; Dadlez M
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Jun; 928():9-15. PubMed ID: 23584041
[TBL] [Abstract][Full Text] [Related]
28. Milrinone therapeutic drug monitoring in a pediatric population: Development and validation of a quantitative liquid chromatography-tandem mass spectrometry method.
Raizman JE; Taylor K; Parshuram C; Colantonio DA
Clin Chim Acta; 2017 May; 468():71-75. PubMed ID: 28131674
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic drug monitoring of topiramate by liquid chromatography-tandem mass spectrometry.
Matar KM
Clin Chim Acta; 2010 May; 411(9-10):729-34. PubMed ID: 20138857
[TBL] [Abstract][Full Text] [Related]
30. Immunosuppressant therapeutic drug monitoring by LC-MS/MS: workflow optimization through automated processing of whole blood samples.
Marinova M; Artusi C; Brugnolo L; Antonelli G; Zaninotto M; Plebani M
Clin Biochem; 2013 Nov; 46(16-17):1723-7. PubMed ID: 24012696
[TBL] [Abstract][Full Text] [Related]
31. Low plasma concentrations of albumin influence the affinity column-mediated immunoassay method for the measurement of tacrolimus in blood during the early period after liver transplantation.
Tempestilli M; Di Stasio E; Basile MR; Elisei F; Antonini M; Ettorre GM; Iappelli M; Pucillo LP
Ther Drug Monit; 2013 Feb; 35(1):96-100. PubMed ID: 23191996
[TBL] [Abstract][Full Text] [Related]
32. Measurement of Teicoplanin Concentration With Liquid Chromatography-Tandem Mass Spectrometry Method Demonstrates the Usefulness of Therapeutic Drug Monitoring in Hematologic Patient Populations.
Chae H; Lee JJ; Cha K; Her SH; Kim HY; Han E; Kim M; Kim Y; Cho SY; Lee DG
Ther Drug Monit; 2018 Jun; 40(3):330-336. PubMed ID: 29746433
[TBL] [Abstract][Full Text] [Related]
33. A rapid, simple and sensitive liquid chromatography-tandem mass spectrometry method for routine clinical monitoring of tacrolimus with the Waters Masstrak™ immmunosuppressant kit.
Guilhaumou R; Lacarelle B; Sampol-Manos E
Methods Find Exp Clin Pharmacol; 2010 Dec; 32(10):737-43. PubMed ID: 21225010
[TBL] [Abstract][Full Text] [Related]
34. LC-MS application for therapeutic drug monitoring in alternative matrices.
Avataneo V; D'Avolio A; Cusato J; Cantù M; De Nicolò A
J Pharm Biomed Anal; 2019 Mar; 166():40-51. PubMed ID: 30609393
[TBL] [Abstract][Full Text] [Related]
35. Quantification of Free Phenytoin by Liquid Chromatography Tandem Mass Spectrometry (LC/MS/MS).
Peat J; Frazee C; Garg U
Methods Mol Biol; 2016; 1383():241-6. PubMed ID: 26660192
[TBL] [Abstract][Full Text] [Related]
36. Bioanalytical LC-MS/MS validation of therapeutic drug monitoring assays in oncology.
van Nuland M; Rosing H; Schellens JHM; Beijnen JH
Biomed Chromatogr; 2020 Jan; 34(1):e4623. PubMed ID: 31215049
[TBL] [Abstract][Full Text] [Related]
37. Liquid chromatography-tandem mass spectrometry outperforms fluorescence polarization immunoassay in monitoring everolimus therapy in renal transplantation.
Moes DJ; Press RR; de Fijter JW; Guchelaar HJ; den Hartigh J
Ther Drug Monit; 2010 Aug; 32(4):413-9. PubMed ID: 20535052
[TBL] [Abstract][Full Text] [Related]
38. An introduction to drug testing: the expanding role of mass spectrometry.
Hammett-Stabler C; Cotten SW
Methods Mol Biol; 2012; 902():1-13. PubMed ID: 22767103
[TBL] [Abstract][Full Text] [Related]
39. Mass spectrometric characterization of toremifene metabolites in human urine by liquid chromatography-tandem mass spectrometry with different scan modes.
Lu J; Wang X; Xu Y; Dong Y; Yang S; Wu Y; Qin Y; Wu M
Analyst; 2011 Feb; 136(3):467-72. PubMed ID: 21113546
[TBL] [Abstract][Full Text] [Related]
40. [Monitoring of immunosuppressant drugs].
Rentsch KM
Ther Umsch; 2008 Sep; 65(9):545-50. PubMed ID: 18791969
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
